• Share
  • Email
  • Print

Coleman Wombwell

Fax +1.704.331.7598

Coleman Wombwell is an associate in the Charlotte office.

His experience includes advising companies throughout the initial public offering process, assisting public companies with Exchange Act and Section 16 reporting and stockholder meetings, representing issuers in a variety of public and private offerings of equity and debt securities, and advising clients with respect to corporate governance practices. In addition, Mr. Wombwell has assisted both public and private clients in mergers, acquisitions, joint ventures and similar corporate transactions.

Professional Background

Prior to joining K&L Gates, Mr. Wombwell was an associate in the corporate/securities group of another international law firm.

  • Represented immunotherapy company developing treatment for cancer and autoimmune disease in connection with its $66 million initial public offering and listing on the Nasdaq Capital Market
  • Represented Nasdaq-listed developer of radio filter products in Rule 144A private placement of convertible secured notes and concurrent public offerings of common stock and convertible notes aggregating $55 million 
  • Represented molecular diagnostics company focused on colorectal cancer screening technology in $150 million follow-on offering of registered notes 
  • Assisted regional health system in affiliation with behavioral health provider with $30 million operating budget by member substitution of a non-profit corporation 
  • Represented medical device company developing novel ultrasound technology in connection with its initial public offering and listing on the Nasdaq Capital Market, private placement of secured convertible notes and multiple follow-on offerings of common stock 
  • Represented rent-to-own company in issuance of preferred equity to multi-national institutional investor, uplisting to the Nasdaq Capital Market and public offering of common stock and warrants 
  • Assisted private equity-backed scent marketing company with acquisition of competitor with operations in Asia, Australia, Europe and North America 
  • Represented national specialty surgery center in restructuring and related private offering of preferred equity 
  • Represented Nasdaq-listed life science company in merger with Japan-based competitor 
  • Represented regional healthcare system in formation of multiple ambulatory surgery center joint ventures